While conducting research in his lab at Yale University, TrialNet Chair Kevan Herold, MD, discovered an interesting outcome. Mouse models (mice genetically modified to mimic a human condition) treated with multiple antibiotics did not respond to the immune therapy teplizumab, the only FDA-approved treatment to delay the onset of type 1 diabetes (T1D). 

From camper to director of the largest camping association serving people with diabetes

When Lisa Gier attended her first diabetes camp at Camp Hodia (a mix of Idaho and diabetes) at age 10, she had no idea she would build an amazing career in camping.

When Maisie Mische, a 22-year-old mechanical engineering student at Marquette University, started having trouble with her vision last year, she attributed the problem to eye fatigue from late-night studying. But two episodes of double vision and subsequent tests revealed something more complex: type 1 diabetes (T1D).

As we begin a new year, it’s the perfect time to celebrate our accomplishments. We recently spoke with TrialNet Chair Kevan Herold, MD, to get his insights on the past year and plans for the year ahead. Dr. Herold is a professor of immunobiology and medicine at Yale University, one of 17 TrialNet Clinical Centers at the forefront of type 1 diabetes research.

The Tremblay family (Laura, 2^nd from right; Bella, far left).

Laura Tremblay’s type 1 diabetes (T1D) journey began in 2018, when her 9-year-old daughter, Bella, was admitted to the hospital in diabetic ketoacidosis (DKA). Like many families without a history of T1D, the Tremblays didn’t recognize the symptoms.

More than a quarter million people screened for risk

For 10-year-old Brynlee Clevenger, it was the possibility of helping other kids with type 1 diabetes (T1D) that prompted her to join a clinical trial.

Pathway to Prevention Study Chair Laura Jacobsen, MD, is an assistant professor and pediatric endocrinologist at the University of Florida, Gainesville.

With four boys who are active in multiple sports, the Ebners are a busy family. But when one of the Ebner sons was diagnosed with type 1 diabetes (T1D), the family made the time for T1D research.

World-first study findings by Australian researchers show a daily pill containing the JAK inhibitor baricitinib can preserve insulin production in people newly diagnosed with T1D. Published in the December issue of the New England Journal of Medicine, findings were co-authored by Thomas Kay, MBBS, PhD,  and Helen Thomas, PhD, St.